Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 32, Issue 10, 2005, Pages 1176-1185

  Colloby, Sean J ^a   Williams, E David ^b   Burn, David J ^c   Lloyd, Jim J ^d   McKeith, Ian G ^a   O'Brien, John T ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b SUNDERLAND ROYAL HOSPITAL   (United Kingdom)

^c NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^d ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

123I FP CIT; Dementia with Lewy bodies; Disease progression; Parkinson's disease; SPECT

Indexed keywords

DOPAMINE; N FLUOROPROPYL 2BETA CARBOMETHOXY 3BETA (4 IODOPHENYL)NORTROPANE I 123; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

AGED; ANALYTIC METHOD; ARTICLE; AUTOANALYSIS; CALCULATION; CAUDATE NUCLEUS; CLINICAL OBSERVATION; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMENTIA; DISEASE COURSE; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; LEWY BODY; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; NERVE DEGENERATION; NEUROBIOLOGY; NEUROIMAGING; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PUTAMEN; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; CORPUS STRIATUM; DEMENTIA; DISEASE PROGRESSION; DOPAMINE; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; PARKINSON DISEASE; RADIOPHARMACEUTICALS; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 25144449559     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-1830-z     Document Type: Article

References (38)

1. Rahkonen T, Eloniemi-Sulkava U, Rissanen S, Vatanen A, Viramo P, Sulkava R. Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older. J Neurol Neurosurg Psychiatry 2003;74:720-4
2. Rabins P, Blacker D, Bland W, BrightLong L, Cohen E, Katz I, et al. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. Am J Psychiatr 1997;154:1-39
3. de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON collaborative study. European community concerted action on the epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62:10-5
4. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 2001;56:730-6
5. Aarsland D, Litvan I, Salmon D, Galasko D, Wentzel-Larsen T, Larsen JP. Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003;74:1215-20
6. Noe E, Marder K, Bell KL, Jacobs DM, Manly JJ, Stem Y. Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia. Mov Disord 2004;19:60-7
7. Burn DJ, Rowan EN, Minett T, Sanders J, Myint P, Richardson J, Thomas A, Newby J, Reid J, O'Brien JT, McKeith IG. Extra-pyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: a cross-sectional comparative study. Mov Disord 2003;18:884-9
8. Bonelli SB, Ransmayr G, Steffelbauer M, Lukas T, Lampl C, Deibl M. L-Dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia. Neurology 2004;63:376-8
9. O'Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004;61:919-25
10. 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med 1997;24:320-5
11. Walker Z, Costa DC, Walker RW, Lee L, Livingston G, Jaros E, et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology 2004;62:1568-72
12. Walker Z, Costa DC, Walker RWH, Shaw K, Gacinovic S, Stevens T, et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002;73:134-40
13. 18F]dopa PET. J Neurol Neurosurg Psychiatry 1998;64:314-9
14. 18F]CFT PET. Synapse 2003;48:109-15
15. Nurmi E, Ruottinen HM, Bergman J, Haaparanta M, Solin O, Sonninen P, Rinne JO. Rate of progression in Parkinson's disease: a 6-F-18 fluoro-L-dopa PET study. Mov Disord 2001;16:608-15
16. 18F]CFT. Ann Neurol 2000;47:804-8
17. 18F]dopa PET. J Neurol Neurosurg Psychiatry 1998;64:314-9
18. Chouker M, Tatsch K, Linke R, Pogarell O, Hahn K, Schwarz J. Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years. Nucl Med Commun 2001;22:721-5
19. Marek K, Innis R, van Dyck C, Fussell B, Early M, Eberly S, et al. I-123 beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 2001;57:2089-94
20. Winogrodzka A, Bergmans P, Booij J, van Royen EA, Stoof JC, Wolters EC. I-123 beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;74:294-8
21. Pirker W, Djamshidian S, Asenbaum S, Gerschlager W, Tribl G, Hoffmann M, et al. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov Disord 2002;17:45-53
22. 123I]beta-CIT SPECT. J Neural Transm 2000;107:543-52
23. 123I-FP-CIT SPECT in dementia with Lewy bodies, Alzheimer's disease and Parkinson's disease. Neuroimage 2004;23:956-66
24. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98
25. Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, Verma S, Goddard R. CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 1986;149:698-709
26. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-14
27. Fahn S, Elton RL, Marsden CD, Goldstein M. Unified Parkinson's disease rating scale. In: Fahn S, Marsden C, Calne D, editors. Recent developments in Parkinson's disease. New York: Macmillan; 1987. p. 153-63
28. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-24
29. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-52
30. 123I] beta-CIT. Mov Disord 1999;14:436-42
31. Ahlskog JE, Uitti RJ, O'Connor MK, Maraganore DM, Matsumoto JY, Stark KF, et al. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov Disord 1999;14:940-6
32. Collins DL, Neelin P, Peters TM, Evans AC. Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J Comput Assist Tomogr 1994;18:192-205
33. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003;54:93-101
34. Marek K, Innis R, van Dyck C, Fussell B, Early M, Eberly S, et al. I-123 beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 2001;57:2089-94
35. Winogrodzka A, Bergmans P, Booij J, van Royen EA, Stoof JC, Wolters EC. I-123 beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;74:294-8
36. Nurmi E, Ruottinen HM, Bergman J, Haaparanta M, Solin O, Sonninen P, et al. Rate of progression in Parkinson's disease: a 6- F-18 fluoro-L-dopa PET study. Mov Disord 2001;16:608-15
37. Pirker W, Holler I, Gerschlager W, Asenbaum S, Zettinig G, Brucke T. Measuring the rate of progression of Parkinson's disease over a 5-year period with beta-CIT SPECT. Mov Disord 2003;18:1266-72
38. Seibyl JP, Laruelle M, van Dyck CH, Wallace E, Baldwin RM, Zoghbi S, et al. Reproducibility of iodine-123-beta-CIT SPECT brain measurement of dopamine transporters. J Nucl Med 1996;37:222-8